The total number of records retrieved from this search are 41. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_1139	Virus nameHerpes simplex virus	Virus strainMutant	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for gamma 34.5, lacZ and alpha 47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01MOI	In-vitro resultKill cancer cell line after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID16278413
IDOV_1140	Virus nameHerpes simplex virus	Virus strainMutant	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for gamma 34.5, lacZ and alpha 47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1MOI	In-vitro resultKill cancer cell line after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID16278413
IDOV_1262	Virus nameAdenovirus	Virus strainAxdAdb-3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDouble mutated for E1A and E1B gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell lineLNCaP	Concentration of cell line3.0E+3 cells per well	In-vitro toxicity	AssayMTT assay	In-vitro virus concentration30 MOI	In-vitro resultSurviving cell number reached to 1000	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18063085
IDOV_1278	Virus nameAdenovirus	Virus strainOBP-301	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit by Roche Diagnostics	In-vitro virus concentration0.1 MOI	In-vitro result98% cell viablity after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18274558
IDOV_1279	Virus nameAdenovirus	Virus strainOBP-301	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit by Roche Diagnostics	In-vitro virus concentration0.1 MOI	In-vitro result90% cell viablity after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18274558
IDOV_1280	Virus nameAdenovirus	Virus strainOBP-301	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit by Roche Diagnostics	In-vitro virus concentration0.1 MOI	In-vitro result70% cell viabilty after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18274558
IDOV_1281	Virus nameAdenovirus	Virus strainOBP-301	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit by Roche Diagnostics	In-vitro virus concentration0.1 MOI	In-vitro result20% cell viability after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18274558
IDOV_1282	Virus nameAdenovirus	Virus strainOBP-301	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit by Roche Diagnostics	In-vitro virus concentration1 MOI	In-vitro result100% cell viability after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18274558
IDOV_1283	Virus nameAdenovirus	Virus strainOBP-301	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit by Roche Diagnostics	In-vitro virus concentration1 MOI	In-vitro result70 % cell viability after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18274558
IDOV_1284	Virus nameAdenovirus	Virus strainOBP-301	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit by Roche Diagnostics	In-vitro virus concentration1 MOI	In-vitro result20% cell viability after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18274558
IDOV_1285	Virus nameAdenovirus	Virus strainOBP-301	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit by Roche Diagnostics	In-vitro virus concentration1 MOI	In-vitro result20% cell viability after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18274558
IDOV_1286	Virus nameAdenovirus	Virus strainOBP-301	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit by Roche Diagnostics	In-vitro virus concentration10 MOI	In-vitro result80% cell viability after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18274558
IDOV_1287	Virus nameAdenovirus	Virus strainOBP-301	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit by Roche Diagnostics	In-vitro virus concentration10 MOI	In-vitro result50% cell viability after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18274558
IDOV_1288	Virus nameAdenovirus	Virus strainOBP-301	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit by Roche Diagnostics	In-vitro virus concentration10 MOI	In-vitro result20% cell viability after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18274558
IDOV_1289	Virus nameAdenovirus	Virus strainOBP-301	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit by Roche Diagnostics	In-vitro virus concentration10 MOI	In-vitro result20% cell viability after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18274558
IDOV_2018	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line7.5E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.1 MOI	In-vitro result90% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2019	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line7.5E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 MOI	In-vitro result60% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2020	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line7.5E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration10 MOI	In-vitro result20% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2021	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line7.5E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2031	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with Docetaxel (7.5 nM)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line7.5E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.125 MOI	In-vitro result70% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2032	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with Docetaxel (15 nM)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line7.5E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.25 MOI	In-vitro result70% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2033	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with Docetaxel (30 nM)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line7.5E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.5 MOI	In-vitro result60% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2034	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with Docetaxel (60 nM)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line7.5E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 MOI	In-vitro result50% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2035	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with Docetaxel (120 nM)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line7.5E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration2 MOI	In-vitro result40% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2046	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with Docetaxel (5 mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismMice injected with PC3 cell line	In-vivo virus concentration1.0E+8 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume after day 15	Mode of deliveryIntratumoral	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_3171	Virus nameSemliki forest virus	Virus strainSFV-VA7	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line40000 cells per well	In-vitro toxicityNA	AssayCalcein AM assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28557974
IDOV_3172	Virus nameSemliki forest virus	Virus strainSFV-VA7	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line40000 cells per well	In-vitro toxicityNA	AssayCalcein AM assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28557974
IDOV_3173	Virus nameSemliki forest virus	Virus strainSFV-VA7	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line40000 cells per well	In-vitro toxicityNA	AssayCalcein AM assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28557974
IDOV_3174	Virus nameSemliki forest virus	Virus strainSFV-VA7	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line40000 cells per well	In-vitro toxicityNA	AssayCalcein AM assay	In-vitro virus concentration10 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28557974
IDOV_3175	Virus nameSemliki forest virus	Virus strainSFV-VA7	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismCAnM.Cg-Foxn1nu/Crl Balb/c nude mice subcutaneous xenograft for LNCaP (5.0E+6)	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor volume after 20 days	Mode of deliveryIntraperitoneal	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28557974
IDOV_3176	Virus nameSemliki forest virus	Virus strainSFV-VA7	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismCAnM.Cg-Foxn1nu/Crl Balb/c nude mice subcutaneous xenograft for LNCaP (5.0E+6)	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor volume after 20 days	Mode of deliveryIntraperitoneal	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28557974
IDOV_3530	Virus nameAdenovirus	Virus strainAdenovirus ZD55	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion in E1B55 viral protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result60% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID28880012
IDOV_3531	Virus nameAdenovirus	Virus strainAdenovirus ZD55	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion in E1B55 viral protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result45% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID28880012
IDOV_3532	Virus nameAdenovirus	Virus strainAdenovirus ZD55	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion in E1B55 viral protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result30% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID28880012
IDOV_3533	Virus nameAdenovirus	Virus strainAdenovirus ZD55	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion in E1B55 viral protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration20 MOI	In-vitro result18% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID28880012
IDOV_3534	Virus nameAdenovirus	Virus strainAdenovirus GD55	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationGOLPH2 regulated aoncolytic adenovirus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result45% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID28880012
IDOV_3535	Virus nameAdenovirus	Virus strainAdenovirus GD55	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationGOLPH2 regulated aoncolytic adenovirus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result20% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID28880012
IDOV_3536	Virus nameAdenovirus	Virus strainAdenovirus GD55	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationGOLPH2 regulated aoncolytic adenovirus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result20% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID28880012
IDOV_3537	Virus nameAdenovirus	Virus strainAdenovirus GD55	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationGOLPH2 regulated aoncolytic adenovirus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration20 MOI	In-vitro result15% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID28880012
IDOV_3726	Virus nameVesicular stomatitis virus	Virus strainVSV-GP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationvirus expressing GP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell lineNA	In-vitro toxicityNA	AssayAbsorbance measurements	In-vitro virus concentration0.1 MOI	In-vitro result70% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryVirus induce apoptosis in cancer cell	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID29696636
IDOV_3733	Virus nameVesicular stomatitis virus	Virus strainVSV-GP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationvirus expressing GP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell lineNA	In-vitro toxicityNA	AssayAbsorbance measurements	In-vitro virus concentration10 MOI	In-vitro result15% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryVirus induce apoptosis in cancer cell	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID29696636